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Abstract
An evaluation of a recent study by Frat JP, Thille AW, Mercat A et al: High-Flow
Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. New
England Journal of Medicine 2015;372(23):2185-96. PubMed PMID:
25981908. Clinicaltrials.gov number NCT01320384.
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Background
Whether noninvasive ventilation should be administered in patients 
with acute hypoxemic respiratory failure is debated. Therapy with 
high-flow oxygen through a nasal cannula may offer an alternative 
in patients with hypoxemia.
Methods
Objective
To determine whether high-flow nasal cannula oxygen therapy 
reduces the need for intubation in patients with acute hypoxemic 
respiratory failure without hypercapnia.
Design
Prospective, randomized, multicenter, open-label 3-arm trial.
Setting
Twenty-three intensive care units in France and Belgium.
Subjects
A total of 310 patients without hypercapnia who had acute hypox-
emic respiratory failure and a ratio of the partial pressure of arterial 
oxygen to the fraction of inspired oxygen (P/F ratio) of 300 mm Hg 
or less on face mask oxygen. Patients with hypercarbia, chronic res-
piratory failure, obstructive lung disease or congestive heart failure 
exacerbation or acute indication for intubation were excluded.
Intervention
High-flow oxygen therapy using the OptiFlow device, standard 
oxygen therapy delivered through a face mask, or noninvasive 
positive-pressure ventilation.
Outcomes
The primary outcome was the proportion of patients intubated at 
day 28; secondary outcomes included all-cause mortality in the 
intensive care unit and at 90 days and the number of ventilator-free 
days at day 28.
Results
The intubation rate (primary outcome) was 38% (40 of 106 patients) 
in the high-flow–oxygen group, 47% (44 of 94) in the standard 
group, and 50% (55 of 110) in the noninvasive-ventilation group 
(P = 0.18 for all comparisons). The number of ventilator-free days 
at day 28 was significantly higher in the high-flow–oxygen group 
(24 +/- 8 days, vs. 22 +/- 10 in the standard-oxygen group and 
19 +/- 12 in the noninvasive-ventilation group; P = 0.02 for all 
comparisons).The hazard ratio for death at 90 days was 2.01 (95% 
confidence interval [CI], 1.01 to 3.99) with standard oxygen versus 
high-flow oxygen (P = 0.046) and 2.50 (95% CI, 1.31 to 4.78) with 
noninvasive ventilation versus high-flow oxygen (P = 0.006).
Conclusions
In patients with nonhypercapnic acute hypoxemic respiratory failure, 
treatment with high-flow oxygen, standard oxygen, or noninvasive 
ventilation did not result in significantly different intubation rates. 
There was a significant difference in favor of high-flow oxygen in 
90-day mortality.
Abstract adapted from the original provided courtesy of PubMed: 
A service of the National Library of Medicine and the National 
Institutes of Health.
Commentary
Acute respiratory failure (ARF) accounts for one-third of inten-
sive care unit (ICU) admission, resulting in a twofold increase in 
ICU mortality and prolonged ICU length of stay2,3. ARF requir-
ing endotracheal intubation and mechanical ventilation brings 
increased risk of mortality and morbidity, yet the optimal time to 
initiate ventilator support remains unclear. Noninvasive positive-
pressure ventilation (NIPPV) reduces the risk of intubation and 
mortality in patients with hypercarbic ARF from exacerbation of 
obstructive lung disease4 and in patients with cardiogenic pulmo-
nary edema4,5. NIPPV has not shown consistent benefits in patients 
with hypoxemic ARF from pneumonia or acute respiratory distress 
syndrome (ARDS), with some suggestion of worsened outcomes 
with “de novo” pneumonia6,7. NIPPV may prevent secretion clear-
ance and is not advisable on patients unable to remove the mask 
due to aspiration risk6,7. In such patients, alternative means of 
non-invasive respiratory support may be desirable.
High-flow nasal cannula (HFNC) oxygen devices deliver up to 
40–60L/min at a precise fraction of inspired oxygen (FiO2). High 
flow rates match the patient’s peak inspiratory flow to prevent room 
air entrainment and improve comfort, while heat and humidification 
may prevent airway desiccation to improve mucociliary clearance8. 
By flushing carbon dioxide from the airways, HFNC reduces ana-
tomic dead space to increase ventilatory efficiency and reduce work 
of breathing, in addition to producing minimal levels of positive 
end-expiratory pressure8.
The FLORALI study randomized 310 patients with hypoxemic 
ARF to nonrebreather face mask, HFNC using the OptiFlow device 
(Fisher and Paykel Healthcare) or NIPPV with inspiratory pressure 
titrated to achieve tidal volume 7–10cc/kg1. The majority of patients 
had pneumonia and met criteria for ARDS, with bilateral infiltrates 
and a ratio of P
a
O2 to FiO2 (P/F ratio) <=200 on face mask oxygen. 
The study excluded patients likely to benefit from NIPPV, including 
those with hypercarbia, exacerbations of obstructive lung disease 
or cardiogenic pulmonary edema, along with patients likely to be 
harmed by NIPPV, including those with hemodynamic instability 
or depressed mental status. There was no significant reduction in 
the rate of intubation between groups in the main study popula-
tion (p = 0.18). A post hoc subgroup analysis in patients with a PF 
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ratio <=200 showed a significantly higher risk of intubation with 
face-mask oxygen (HR 2.07) or NIPPV (HR 2.57) compared to 
HFNC (p = 0.009). HFNC was associated with lower mortality in 
the ICU (p = 0.047) and at 90 days (p = 0.02) in both unadjusted and 
adjusted analyses, with HR’s ranging from 1.85 to 2.60. Patients in 
the HFNC group had more ventilator-free days and lower dyspnea 
scores.
Strengths of this study include multi-center, randomized, intention- 
to-treat design with enrollment from 23 large ICU’s9. Patients 
expected to benefit from NIPPV were systematically excluded. 
Since rate of intubation was the primary endpoint, a protocol was 
used to standardize indications for intubation. Study groups were 
well-matched at baseline and follow-up was complete. The study 
has a number of limitations that must be considered when apply-
ing the results. This was a highly-selected population enriched in 
patients with ARDS due to pneumonia without obstructive lung 
disease or heart failure; only 21% of screened patients with hypox-
emic ARF were eligible and 12.5% were included. Patients had lim-
ited extrapulmonary organ failure, which is a risk factor for HFNC 
failure in ARDS10. The study had limited statistical power for the 
primary endpoint, with an observed intubation rate of 45% com-
pared to an anticipated intubation rate of 60%. Because the study 
failed to meet its prespecified primary endpoint, the significant 
results of the post hoc subgroup analysis and the secondary mor-
tality endpoints are hypothesis-generating rather than conclusive. 
One-fourth of patients in the face mask arm and one-eighth of 
patients in the HFNC arm crossed over to receive NIPPV; approxi-
mately two-thirds of these patients required intubation. It remains 
unclear why fewer people died in the HFNC arm, although the 
7–10cc/kg tidal volume in the NIPPV arm exceeds the recom-
mended 6cc/kg that has been associated with lower mortality in 
patients with ARDS11,12. Protocolized intubation criteria may have 
delayed intubation, as reflected by the occurrence of two deaths 
during intubation. While the study’s protocolized intubation criteria 
seem reasonable as part of a research study, the decision to intubate 
requires considerable judgment and is difficult to fit to a protocol.
The FLORALI study emphasizes that the approach noninvasive 
respiratory support in ARF should be tailored to both the under-
lying physiology (hypoxemic versus hypercarbic ARF) and the 
causative disease process. HFNC may become the preferred 
noninvasive modality for patients with hypoxemic ARF due to pneu-
monia or ARDS, while NIPPV will remain preferred for patients 
with obstructive lung disease or cardiogenic pulmonary edema. 
Other recent studies of HFNC have shown mixed results depend-
ing on the population studied. HFNC failed to show a benefit over 
NIPPV for pre-oxygenation prior to intubation, although HFNC 
during intubation did reduce the risk of desaturation during intuba-
tion when compared to face mask13,14. HFNC was inferior to NIPPV 
for respiratory support during bronchoscopy15. HFNC performed 
equally compared to NIPPV for patients developing ARF after 
cardiothoracic surgery16. Further studies are needed to guide our 
use of HFNC for patients with ARF, and several ongoing studies of 
HFNC are listed on clinicaltrials.gov.
Recommendation
HFNC is safe and can be considered for first line support of 
patients with severe hypoxemic ARF not requiring immediate 
intubation, including pneumonia and early ARDS in the absence 
of hypercarbia, obstructive lung disease or heart failure exacer-
bation. Careful monitoring in an ICU during HFNC is essen-
tial to ensure timely escalation of therapy in the event of HFNC 
failure. With either HFNC or NIPPV, intubation should be per-
formed before the patient exhausts their physiologic reserves and 
decompensates.
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